Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access ProgramGlobeNewsWire • 04/23/24
Tiziana Life Sciences reports additional positive results from Multiple Sclerosis programProactive Investors • 04/22/24
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access ProgramGlobeNewsWire • 04/22/24
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®GlobeNewsWire • 04/19/24
Tiziana Life Sciences says foralumab shows promise in stabilizing certain types of MSProactive Investors • 04/18/24
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/18/24
Tiziana Life Sciences to present new imaging data for lead asset at upcoming neurology conferenceProactive Investors • 04/11/24
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of NeurologyGlobeNewsWire • 04/11/24
Tiziana Life Sciences to present positive data for lead drug candidate in Alzheimer's diseaseProactive Investors • 03/05/24
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer's DiseaseGlobeNewsWire • 03/05/24
Tiziana Life Sciences reveals positive clinical, PET scan findings for intranasal Foralumab in MS patientsProactive Investors • 01/08/24
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis PatientsGlobeNewsWire • 01/08/24
Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024GlobeNewsWire • 01/05/24
Tiziana Life Sciences files patent for foralumab combination therapy for obesity-associated inflammationProactive Investors • 01/05/24
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated InflammationGlobeNewsWire • 01/05/24
Tiziana Life Sciences doses first patient in mid-stage multiple sclerosis studyProactive Investors • 12/19/23
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple SclerosisGlobeNewsWire • 12/19/23
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment WebinarGlobeNewsWire • 12/04/23
Tiziana Life Sciences advances multiple sclerosis research program with enrollment and dosing of patientsProactive Investors • 11/30/23
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple SclerosisGlobeNewsWire • 11/30/23
Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023GlobeNewsWire • 11/01/23
Tiziana Life Sciences: FDA signs off on home-based protocol fo MS treatmentProactive Investors • 10/18/23
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis TreatmentGlobeNewsWire • 10/18/23
Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent resultsProactive Investors • 10/16/23